Abstract. Numerous studies have identified the dysregulation of microRNAs (miRNAs) in cervical cancer, and dysregulated miRNAs are involved in regulating a number of tumourassociated biological behaviours. Therefore, investigating the roles of cervical cancer-associated miRNAs and the underlying molecular mechanisms is essential for the development of novel diagnostic biomarkers and effective therapeutic targets. MicroRNA-432 (miR-432) dysregulation has been revealed to be implicated in the carcinogenesis and progression of a number of types of human cancer. However, the effects and underlying molecular mechanisms of miR-432 in cervical cancer have yet to be elucidated. In the present study, miR-432 expression was determined using reverse transcription-quantitative polymerase chain reaction. The results revealed that miR-432 was expressed at low levels in cervical cancer tissues and cell lines. Decreased miR-432 expression was significantly associated with the International Federation of Gynecology and Obstetrics stage, myometrium invasion and lymph node metastasis of patients with cervical cancer. Following transfection with miR-432 mimic, the expression of miR-432 was significantly upregulated in cervical cancer cells. Upregulation of miR-432 expression restricted the proliferation and invasion of cervical cancer cells. Bioinformatics analysis followed by luciferase reporter assays revealed that fibronectin 1 (FN1) was a direct target gene of miR-432 in cervical cancer cells. In addition, FN1 was upregulated in cervical cancer tissues and was inversely correlated with miR-432 levels. Furthermore, miR-432 upregulation decreased the expression levels of FN1 in cervical cancer cells at the mRNA and protein levels. Furthermore, silencing of FN1 could stimulate the tumour suppressor effects of miR-432 upregulation in cervical cancer cells. In addition, restored FN1 expression neutralized the effects of miR-432 overexpression in cervical cancer cells. The results of the present study indicate that miR-432 is a tumour suppressor that can restrain the aggressive phenotype of cervical cancer cells by directly targeting FN1, suggesting that this miRNA may be developed as an effective therapeutic strategy for patients with cervical cancer.
Introduction
Cervical cancer, one of the most common types of gynaecological malignancy, is the fourth most frequent cause of cancer-associated mortality among females worldwide (1). The incidence of cervical cancer is decreasing each year in developed countries; unfortunately, however, it continues to increase each year in developing countries (2) . It is estimated that there are ~500,000 novel cases and >250,000 mortalities caused by cervical cancer per year globally (3) . In recent years, impressive progress has been made in diagnostic techniques and therapeutic approaches; however, cervical cancer remains a public health concern worldwide, and the clinical outcomes of patients with cervical cancer remain unsatisfactory (4) . Multiple factors, such as local recurrence, distant metastasis and diagnostic delays, are mainly responsible for the poor prognosis of patients with cervical cancer (5); however, the specific underlying molecular mechanism remains largely unknown. Thus, further studies are required to elucidate the molecular mechanisms underlying cervical carcinogenesis and progression to develop promising therapeutic methods for treating patients with cervical cancer.
MicroRNAs (miRNAs) are a subset of endogenous, non-coding and small RNA molecules (2) . These 17-23-nucleotide-long RNAs are able to post-transcriptionally modulate the expression of relevant genes via base-pairing with the 3'-untranslated regions (3'-UTRs) of their target genes, thereby resulting in either translation suppression and/or mRNA cleavage (6) . To date, >1,500 mature miRNAs have been identified in the human genome, and these miRNAs can regulate ~30% of human protein-coding genes (6) . miRNA aberrations have been identified in various types of malignancy, including cervical cancer (7) . It has been demonstrated that a number of miRNAs are abnormally expressed during the occurrence and progression of cervical cancer (8) . For example, miR-143 (9), miR-152 (10) and miR-506 (11) were downregulated in cervical cancer, whereas miR-21 (12) , miR-224 (13) and miR-1297 (14) were expressed at high levels. Recent evidence has indicated that deregulated miRNAs may serve crucial roles in cervical cancer initiation and progression by regulating a wide range of biological functions (15) (16) (17) . Therefore, miRNAs may be effective therapeutic targets for the treatment of patients with cervical cancer.
miR-432 dysregulation has been demonstrated to be implicated in the carcinogenesis and progression of numerous types of human cancer, including lung adenocarcinoma (18) , neuroblastoma (19) , hepatocellular carcinoma (20) and prostate cancer (21) . However, the effects and underlying molecular mechanisms of miR-432 in cervical cancer have yet to be elucidated. The objectives of the present study were to detect the expression of miR-432 in cervical cancer and determine its clinical significance. The effects of miR-432 in cervical cancer cells and the potential underlying molecular mechanism of these effects were also investigated.
Materials and methods

Clinical tissue specimens.
A total of 47 pairs of cervical cancer tissues and matched adjacent normal tissues were collected from female patients (age range, 49-65 years) who received surgery at The Third People's Hospital of Linyi (Linyi, China) between April 2015 and August 2017. All tissues were obtained using microdissection. None of these patients had been treated with any pre-operative chemotherapy or radiotherapy. Once obtained, tissues were immediately frozen in liquid nitrogen and then stored at -80˚C for further study. Patients that had been treated with pre-operative chemotherapy or radiotherapy were excluded from the study. All patients with cervical cancer were divided into either a low miR-432 expression group or a high miR-432 expression group using the median value of miR-432 expression (0.45) as the cut-off. The International Federation of Gynecology and Obstetrics (FIGO) stage is currently the most commonly used staging system for cancer of the uterine cervix worldwide (22) . Tumours are classified by roman numerals from I to IV, representing a range from precancerous or in situ to highly malignant. Classification subdivisions are indicated by letters and numbers (22) . The present study was approved by the Ethics Committee of The Third People's Hospital of Linyi. All patients provided written informed consent and were apprised of the aims of the study.
Cell lines. Three human cervical cancer cell lines, HeLa, CaSki and SiHa, were purchased from the Cell Bank of the Chinese Academy of Sciences (Shanghai, China). The normal human cervix epithelial cell line, Ect1/E6E7, was purchased from the American Type Culture Collection (ATCC; Manassas, VA, USA). All cell lines were cultured in Dulbecco's modified Eagle's medium (DMEM) containing 10% foetal bovine serum (FBS), 100 U/ml penicillin and 100 µg/ml streptomycin (all purchased from Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA) and grown in a humidified incubator supplied with 5% CO 2 at 37˚C.
Oligonucleotide transfection. Synthetic miR-432 mimic and negative control miRNA mimic (miR-NC) were obtained from Guangzhou RiboBio Co., Ltd. (Guangzhou, China). For silencing of fibronectin 1 (FN1) expression, a small interfering RNA (siRNA) against FN1 (FN1 siRNA) and negative control siRNA (NC siRNA) were chemically synthesized by GeneCopoeia, Inc. (Rockville, MD, USA). The FN1 expression plasmid pcDNA3.1-FN1 (pc-FN1) and blank pcDNA3.1 plasmid were generated by Shanghai GenePharma Co., Ltd. (Shanghai, China). HeLa and SiHa cells in the exponential growth phase were collected and seeded into 6-well plates at a density of 6x10 6 cells/well 1 day before transfection. Cells were transfected with miRNA mimic (100 pmol), siRNA (100 pmol) or plasmid (4 µg) using Lipofectamine ® 2000 reagent (Invitrogen; Thermo Fisher Scientific, Inc.) according to the manufacturer's protocol. The transfected HeLa and SiHa cells were harvested and used for the detection of miR-432 and FN1 protein expression at 48 and 72 h after transfection, respectively.
RNA extraction and reverse transcription-quantitative polymerase chain reaction (RT-qPCR).
Total RNA was isolated from cell lines and tissues using TRIzol ® reagent (Invitrogen; Thermo Fisher Scientific, Inc.), and the concentration of isolated total RNA was determined using a NanoDrop™ 1000 spectrophotometer (Thermo Fisher Scientific, Inc.). To quantify miR-432 expression, total RNA was converted into cDNA using the TaqMan MicroRNA RT kit (Applied Biosystems; Thermo Fisher Scientific, Inc.). The temperature protocol for reverse transcription was as follows: 16˚C for 30 min, 42˚C for 30 min and 85˚C for 5 min. Next, qPCR was performed using the TaqMan MicroRNA PCR kit (Applied Biosystems; Thermo Fisher Scientific, Inc.). The temperature protocol for qPCR was as follows: 50˚C for 2 min, 95˚C for 10 min; 40 cycles of denaturation at 95˚C for 15 sec; and annealing/extension at 60˚C for 1 min. For FN1 mRNA expression analysis, cDNA was generated from total RNA using the PrimeScript RT Reagent kit followed by qPCR using the SYBR ® Premix Ex Taq™ kit (both from Takara Biotechnology Co., Ltd., Dalian, China). The temperature protocol for reverse transcription was as follows: 37˚C for 15 min and 85˚C for 5 sec. The qPCR was performed with cycling conditions as follows: 5 min at 95˚C, followed by 40 cycles of 95˚C for 30 sec and 65˚C for 45 sec. U6 small nuclear RNA and GAPDH were used as internal references for miR-432 and FN1 mRNA expression, respectively. Relative gene expression was quantified using the 2 -ΔΔCq method (23) . The primers were designed as follows: miR-432 forward, 5'-AAC GAG ACG ACG ACA GAC T-3' and reverse, 5'-CTT GGA GTA GGT CAT TGG GT-3'; U6 forward, 5'-GCT TCG GCA GCA CAT ATA CTA AAA T-3' and reverse, 5'-CGC TTC ACG AAT TTG CGT GTC AT-3'; FN1 forward, 5'-CAG TGG GAG ACC TCG AGA AG-3' and reverse, 5'-TCC CTC GGA ACA TCA GAA AC-3'; and GAPDH forward, 5'-GCT GGC GCT GAG TAC GTC GTG GAG T-3' and reverse, 5'-CACAGTCTTCTGGGTGGCAGTGATGG-3'.
Cell Counting assay. The influence of miR-432 on cervical cancer cell proliferation was evaluated using the CCK-8 assay. Briefly, transfected HeLa and SiHa cells were collected after 24 h of incubation, and 3x10 3 cells/well were inoculated into 96-well plates in triplicate. Following incubation for 0, 24, 48 or 72 h at 37˚C with 5% CO 2 , a CCK-8 assay was performed by adding 10 µl CCK-8 solution (Dojindo Molecular Technologies, Inc., Kumamoto, Japan) to each well.
Cells were then incubated at 37˚C for an additional 2 h. Finally, the optical density at a wavelength of 450 nm was determined using a spectrophotometer (Victor X; PerkinElmer, Inc., Waltham, MA, USA).
Transwell Matrigel invasion assay.
A Transwell Matrigel invasion assay was used to identify the invasive capacity of cervical cancer cells. To this end, transfected cells were harvested after 48 h of incubation and suspended in FBS-free DMEM. In total, 5x10 4 cells were placed in the upper compartment of Transwell inserts that were coated with Matrigel (both purchased from BD Biosciences, San Jose, CA, USA). DMEM supplemented with 20% FBS was added to the lower compartments as a chemoattractant. After 24 h of incubation, non-invasive cells were gently wiped off using a cotton swab. The invasive cells on the bottom side of the membrane were fixed with 4% paraformaldehyde at 37˚C for 15 min and stained with 0.1% crystal violet at 37˚C for 30 min. The invasive ability of cervical cancer cells was assessed by counting the number of invasive cells in five randomly selected visual fields from each insert using a light microscope (x200 magnification; Olympus Corporation, Tokyo, Japan).
Bioinformatics analysis. The databases TargetScan (targetscan. org) and miRDB (mirdb.org) software were used to predicate the putative targets of miR-432.
Luciferase reporter assay. The wild-type (WT) and mutant (MUT) 3'-UTRs of FN1 were amplified by and purchased from Shanghai GenePharma Co., Ltd., and cloned into pMIR (Ambion; Thermo Fisher Scientific, Inc.), generating the pMIR-WT-FN1-3'-UTR and pMIR-MUT-FN1-3'-UTR plasmids, respectively. For the reporter assay, cells in the exponential growth phase were plated on 24-well plates with a density of 1.5x10 5 cells/well. miR-432 mimic (50 pmol) or miR-NC (50 pmol) in combination with pMIR-WT-FN1-3'-UTR (0.2 µg) or pMIR-MUT-FN1-3'-UTR (0.2 µg) were co-transfected into cells using Lipofectamine 2000 reagent, according to the manufacturer's protocol.
Luciferase activity was determined using a dual-luciferase reporter assay system (Promega Corporation, Madison, WI, USA) 48 h after transfection. The activity of firefly luciferase was normalized to that of Renilla luciferase.
Western blot analysis. Tissue samples and cells were washed twice with PBS and lysed with radioimmunoprecipitation assay lysis buffer (Shanghai Qcbio Science & Technologies Co., Ltd., Shanghai, China). The concentration of total protein was determined using a bicinchoninic acid kit (Beyotime Institute of Biotechnology, Haimen, China). Equal amounts of total protein (30 µg) were separated by SDS-PAGE (10% gel) and then transferred onto polyvinylidene difluoride membranes (Beyotime Institute of Biotechnology). Following blocking with 5% skimmed milk suspended in Tris-buffered saline-containing Tween-20 (TBST) at room temperature for 2 h, the membranes were incubated overnight at 4˚C with primary antibodies as follows: Rabbit anti-human FN1 antibody (catalogue no. 15613-1-AP; 1:200 dilution; ProteinTech Group, Inc., Chicago, IL, USA) and rabbit anti-human GAPDH antibody (catalogue no. ab181603; 1:1,000 dilution; Abcam, Cambridge, UK). Following extensive washes with TBST, horseradish peroxidase-conjugated goat anti-rabbit secondary antibody (catalogue no. ab6721; 1:5,000 dilution; Abcam, Cambridge, UK) was added for 2 h at room temperature. Finally, the immunoreactive proteins were visualized using an enhanced chemiluminescence protein detection kit (Pierce; Thermo Fisher Scientific, Inc.). GAPDH was used as a loading control.
Statistical analysis. Data are presented as the mean ± standard deviation. Student's t-test was used to compare the difference between two groups. The differences between multiple groups were evaluated using one-way analysis of variance, followed by Tukey's post hoc test. A χ 2 test was applied to investigate the association between miR-432 and the clinical characteristics in patients with cervical cancer. The correlation between expression levels of miR-432 and FN1 mRNA in cervical cancer tissues was assessed using Spearman's correlation analysis. P<0.05 was considered to indicate a statistically significant difference.
Results
miR-432 expression is decreased and significantly associated with certain clinicopathological features of cervical cancer.
To investigate the clinical value of miR-432 in cervical cancer, the expression levels of miR-432 in 47 pairs of cervical cancer tissues and matched adjacent normal tissues were determined using RT-qPCR. The results revealed a significant decrease in the expression of miR-432 in cervical cancer tissues compared with in adjacent normal tissues (P<0.05; Fig. 1A) . The clinical significance of miR-432 expression in cervical cancer was then investigated. All patients with cervical cancer were divided into either a low miR-432 expression group or a high miR-432 expression group using the median value of miR-expression (0.45) as the cut-off. Decreased miR-432 expression was revealed to be significantly associated with the FIGO stage (P= 0.020), myometrium invasion (P= 0.001) and lymph node metastasis (P= 0.008). However, no significant association was identified with age or tumour size (both P>0.05; Table I ). In addition, the expression level of miR-432 in three human cervical cancer cell lines (HeLa, CaSki and SiHa) and a normal human cervix epithelial cell line (Ect1/E6E7) was determined. RT-qPCR analysis revealed that miR-432 was expressed at low levels in all three cervical cancer cell lines relative to Ect1/E6E7 (P<0.05; Fig. 1B) . These results suggest that downregulation of miR-432 may be involved in the development and progression of cervical cancer.
Ectopic miR-432 expression inhibits the proliferation and invasion of cervical cancer cells. HeLa and SiHa cell lines exhibited the greatest decrease in miR-432 expression among the three cervical cancer cell lines, therefore these two cervical cancer cell lines were selected for subsequent functional assays. To identify the specific roles of miR-432 in cervical cancer cells, miR-432 mimic or miR-NC were introduced into HeLa and SiHa cells. RT-qPCR analysis verified that miR-432 was markedly overexpressed in miR-432 mimic-transfected HeLa and SiHa cells compared with cells transfected with miR-NC and non-transfected cells (P<0.05; Fig. 2A ). In addition, no significant difference in miR-432 expression was observed between the miR-NC and non-transfected groups (P<0.05). A CCK-8 assay was performed in order to investigate the effect of miR-432 overexpression on the proliferation of cervical cancer cells. The results indicated that when HeLa and SiHa cells were transfected with miR-432 mimic, the proliferative ability was significantly decreased compared with that of miR-NC groups at 48 and 72 h (P<0.05; Fig. 2B ). Furthermore, a Transwell Matrigel invasion assay was performed to investigate the effect of miR-432 on cervical cancer cell invasion. It was revealed that enforced miR-432 expression significantly inhibited the invasion of HeLa and SiHa cells (P<0.05; Fig. 2C ). These results suggest that miR-432 may have anti-proliferative and anti-invasive roles in cervical cancer cells.
FN1 is a direct target gene of miR-432 in cervical cancer cells.
To further illustrate the molecular mechanisms by which miR-432 inhibits cervical cancer cell proliferation and invasion, a bioinformatics analysis was performed in order to predict the potential targets of miR-432. A highly conserved putative binding site was revealed at 154-160 bp of the FN1-3'-UTR (Fig. 3A) . FN1 was selected for further investigation as this gene was considered to have a role in the formation and progression of cervical cancer (24) (25) (26) (27) . To confirm this prediction, luciferase reporter plasmids were chemically synthesized and co-transfected with miR-432 mimic or miR-NC into HeLa and SiHa cells. The results of the luciferase reporter assays in the present study indicated that miR-432 overexpression notably decreased the luciferase activity of the plasmid harbouring WT-FN1-3'-UTR (P<0.05); however, the suppression of luciferase activity was eliminated when HeLa and SiHa cells were co-transfected with miR-432 mimic and luciferase plasmid containing MUT-FN1-3'-UTR (Fig. 3B) .
RT-qPCR was performed to determine FN1 expression in 47 pairs of cervical cancer tissues and matched adjacent normal tissues. The data revealed that the expression level of FN1 mRNA was significantly higher in cervical cancer tissues compared with in adjacent normal tissues (P<0.05; Table I . Association between miR-432 and the clinicopathological features of patients with cervical cancer. 
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Discussion
Numerous studies have demonstrated the dysregulation of miRNAs in cervical cancer (28) (29) (30) . miRNAs serve as oncogenes or tumour suppressors and are involved in regulating a number of tumour-associated biological behaviours, including the cell cycle, cell proliferation, apoptosis and metastasis (2) . Therefore, investigating the roles of cervical cancer-associated miRNAs and the underlying molecular mechanisms is essential for the development of novel diagnostic biomarkers and effective therapeutic targets. In the present study, the expression levels and clinical value of miR-432 in cervical cancer were investigated. Furthermore, the detailed roles of miR-432 in the development of cervical cancer were determined. Notably, the underlying molecular mechanisms by which miR-432 may affect the development of cervical cancer were investigated. miR-432 is deregulated in several types of human cancer. For instance, miR-432 was downregulated in lung adenocarcinoma tissues and cell lines. Downregulation of miR-432 was significantly associated with the clinical stage of patients with lung adenocarcinoma. Patients with lung adenocarcinoma that have low miR-432 levels presented with poorer prognoses than those patients with high miR-432 levels (18) . miR-432 was also expressed at low levels in neuroblastoma (19) , hepatocellular carcinoma (20) and prostate cancer (21) . However, the expression status of miR-432 in cervical cancer remains unclear. In the present study, RT-qPCR analysis was used to detect miR-432 expression in cervical cancer tissues and cell lines. The results of the present study revealed that miR-432 was expressed at low levels in cervical cancer tissues and cell lines. In addition, decreased miR-432 expression was associated with FIGO stage, myometrium invasion and lymph node metastasis in patients with cervical cancer. These results suggest that miR-432 may be a potential biomarker for the diagnosis of patients with these specific types of cancer.
miR-432 deregulation contributes to the carcinogenesis and progression of several types of human malignancy. For example, miR-432 re-expression repressed cell proliferation and induced cell cycle arrest in lung adenocarcinoma. In addition, miR-432 overexpression increased the chemosensitivity of lung adenocarcinoma cells to cisplatin (18) . In neuroblastoma, enforced miR-432 expression decreased cell proliferation, promoted G0-G1 cell cycle arrest and induced neurite projections (19) . In hepatocellular carcinoma, restoration of miR-432 expression inhibited cell proliferation and colony formation, increased G0-G1 cell cycle arrest in vitro and decreased tumour growth in vivo through deactivation of the Wnt/β-catenin signalling pathway (20) . In prostate cancer, ectopic miR-432 expression inhibited the activation of the Wnt/β-catenin signalling pathway and participated in the regulation of cell proliferation and apoptosis. Nevertheless, to the best of our knowledge, the functional roles of miR-432 in the progression and development of cervical cancer have not been investigated. In the present study, functional experiments demonstrated that resumption of miR-432 expression restrained the proliferation and invasion of cervical cancer cells. These results suggest that miR-432 may represent a useful therapeutic target for managing patients with these types of malignant tumour.
Several genes have been identified as direct targets of miR-432, including E2F transcription factor 3 and anexelekto in lung adenocarcinoma (18) , nestin and REST corepressor 1 in neuroblastoma (19) and tripartite motif-containing protein 29 and Pygopus homolog 2 in prostate cancer (21) . In the present study, the underlying molecular mechanism by which miR-432 regulates the development of cervical cancer was also investigated. FN1, a member of the FN family (24) , was identified as a direct target of miR-432 in cervical cancer. The expression of FN1 was previously reported to be upregulated in numerous types of human malignant tumours, including breast cancer (31) , gastric cancer (32), ovarian cancer (33) and thyroid cancer (34) . A number of studies have demonstrated the key role that FN1 serves in tumourigenesis and tumour progression; FN1 serves oncogenic roles and regulates a variety of cellular processes (24) (25) (26) (27) . In the present study, it was revealed that FN1 was markedly expressed in cervical cancer, and that inhibition of FN1 could inhibit the proliferation and invasion of cervical cancer cells. These data suggest that targeting FN1 may be a promising approach for treating patients with cervical cancer.
In conclusion, miR-432 was downregulated in cervical cancer, which was correlated with FIGO stage, myometrium invasion and lymph node metastasis. Enforced miR-432 expression suppressed the proliferation and invasion of cervical cancer cells by directly targeting FN1. The results of the present study provide a theoretical basis for the application of the miR-432/FN1 pathway in the treatment of patients with cervical cancer. However, there were two limitations to the present study: First, the influence of miR-432 on the cell cycle of cervical cancer was not investigated. Secondly, the sample size of the present study was small. Future studies will aim to resolve these two limitations.
